MedTrace Logo

Is in Vitro Maturation of Oocytes Influenced by the Origin of Gonadotropins Used in Maturation Medium: is There a Difference in Efficiency When Using Urinary Versus Recombinant Produced Follicle Stimulating Hormone and Human Chorionic Gonadotropin

NCT05370794 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2022-11-07

No results posted yet for this study

Summary

Standard IVM currently contains urinary purified hormones which might contain contaminants possibly affecting maturation of embryo development. The investigators will test if the efficiency in terms of oocyte maturation after IVM of recombinant (without contaminants) is equivalent to urinary gonadotropins. Urinary and recombinant FSH and hCG will be used in equivalent bioactivity as measured in IU/ml and specified by the manufacturer. Sibling oocytes of the patient will be subjected to IVM medium containing urinary or recombinant gonadotropins. Oocyte maturation is the primary outcome, however, fertilization rate and preimplantation embryo development will be investigated.

Conditions

  • In Vitro Maturation of Oocytes

Interventions

DRUG

rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono

recombinant hCG

DRUG

rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono

recombinant FSH

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    lead OTHER

Principal Investigators

  • Michel De Vos, MD,PhD · Universitair Ziekenhuis Brussel

Eligibility

Min Age
18 Years
Max Age
36 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-19
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05370794 on ClinicalTrials.gov